{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:03Z","timestamp":1793262003482,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clinthera.2013.06.014","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T21:31:01Z","timestamp":1375306261000},"page":"1247-1252","source":"Crossref","is-referenced-by-count":16,"title":["The Efficacy of Colesevelam HCl in the Treatment of Heterozygous Familial Hypercholesterolemia in Pediatric and Adult Patients"],"prefix":"10.1016","volume":"35","author":[{"given":"Michael","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.06.014_bib1","series-title":"The Metabolic & Molecular Bases of Inherited Disease","author":"Scriver","year":"2001"},{"key":"10.1016\/j.clinthera.2013.06.014_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.014_bib3","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.ATV.11.5.1368","article-title":"Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia","volume":"11","author":"Gylling","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.clinthera.2013.06.014_bib4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/01.ATV.13.10.1460","article-title":"Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations","volume":"13","author":"Kotze","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.clinthera.2013.06.014_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Qu\u00e9bec province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.clinthera.2013.06.014_bib6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.014_bib7","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2013.06.014_bib8","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1161\/01.CIR.0000058166.99182.54","article-title":"Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children","volume":"107","author":"Wiegman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.014_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.ATV.16.8.984","article-title":"Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects","volume":"16","author":"Tonstad","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2013.06.014_bib10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2013.06.014_bib11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2013.06.014_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.hlc.2012.04.010","article-title":"A new model of care for familial hypercholesterolaemia: what is the role of cardiology?","volume":"21","author":"Watts","year":"2012","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.clinthera.2013.06.014_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.clinthera.2010.04.014","article-title":"Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial","volume":"32","author":"Huijgen","year":"2010","journal-title":"Clin Ther"},{"issue":"231\u2013236","key":"10.1016\/j.clinthera.2013.06.014_bib14","first-page":"e1","article-title":"Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia","volume":"156","author":"Stein","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2013.06.014_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/14779072.6.4.567","article-title":"Familial hypercholesterolemia: current treatment and advances in management","volume":"6","author":"Huijgen","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2013.06.014_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11594970-000000000-00000","article-title":"Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia","volume":"11","author":"Lee","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2013.06.014_bib17","unstructured":"Colestid, Flavored Colestid (colestipol hydrochloride for oral suspension) [prescribing information]. New York, NY: Pfizer Inc; revised June 2006."},{"key":"10.1016\/j.clinthera.2013.06.014_bib18","unstructured":"Cholestyramine for oral suspension, USP [US prescribing information]. Minneapolis, MN: Upsher-Smith Laboratories Inc; revised September 2011."},{"key":"10.1016\/j.clinthera.2013.06.014_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/BF01489714","article-title":"Abnormal low density lipoproteins in children with familial hypercholesterolemia\u2014effect of polyanion exchange resins","volume":"56","author":"Mordasini","year":"1978","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.clinthera.2013.06.014_bib20","unstructured":"Welchol (colesevelam HCl) [US prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; revised June 2012."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2013.06.014_bib21","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2011.03.453","article-title":"National Lipid Association Expert Panel on Familial Hypercholesterolemia. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Daniels","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2013.06.014_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbrc.2005.02.170","article-title":"Feedback regulation of bile acid synthesis in human liver: importance of HNF-4\u03b1 for regulation of CYP7A1","volume":"330","author":"Abrahamsson","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2013.06.014_bib23","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2013.06.014_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00125-011-2382-3","article-title":"Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study","volume":"55","author":"Beysen","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2013.06.014_bib25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2337\/db12-0923","article-title":"The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes","volume":"62","author":"Smushkin","year":"2013","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.06.014_bib26","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142013. Diabetes Care.","volume":"36","year":"2013"},{"key":"10.1016\/j.clinthera.2013.06.014_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.97.5.619","article-title":"Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group","volume":"97","author":"Lambert","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2013.06.014_bib28","doi-asserted-by":"crossref","first-page":"47C","DOI":"10.1016\/j.amjcard.2006.11.022","article-title":"Safety considerations with gastrointestinally active lipid-lowering drugs","volume":"99","author":"Jacobson","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2013.06.014_bib29","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/jps.20734","article-title":"Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages","volume":"95","author":"Hanus","year":"2006","journal-title":"J Pharm Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T18:39:03Z","timestamp":1646246343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813003421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0149291813003421"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.06.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}